BioScrip (BIOS) Misses Q3 EPS by 28c

Go back to BioScrip (BIOS) Misses Q3 EPS by 28c

BioScrip Reports Third Quarter 2015 Financial Results

November 4, 2015 7:00 AM UTC

Consolidated Adjusted EBITDA of $6.2 Million

Results Demonstrate Progress Against Financial Improvement Plan

Reaffirms 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Million

ELMSFORD, N.Y.--(BUSINESS WIRE)-- BioScrip, Inc. (NASDAQ: BIOS) (the Company) today announced 2015 third quarter financial results.

Third Quarter Highlights

Consolidated Adjusted EBITDA was $6.2 million, primarily due to the early positive contributions of BioScrips previously announced plan to reduce costs and focus on its core infusion business; Revenue... More